Blackhawk Capital Partners LLC. Acquires 1,427 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Blackhawk Capital Partners LLC. boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 190.5% during the 4th quarter, Holdings Channel reports. The firm owned 2,176 shares of the medical research company’s stock after buying an additional 1,427 shares during the period. Blackhawk Capital Partners LLC.’s holdings in Bio-Rad Laboratories were worth $715,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in BIO. Strategic Financial Concepts LLC bought a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $3,561,000. Lecap Asset Management Ltd. purchased a new position in Bio-Rad Laboratories during the fourth quarter valued at $510,000. Principal Financial Group Inc. increased its holdings in Bio-Rad Laboratories by 95.6% in the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after acquiring an additional 21,669 shares during the last quarter. Mawer Investment Management Ltd. lifted its stake in Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after purchasing an additional 84,237 shares in the last quarter. Finally, Verition Fund Management LLC boosted its holdings in shares of Bio-Rad Laboratories by 193.3% during the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock valued at $1,161,000 after purchasing an additional 2,287 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on BIO shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Citigroup upped their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company lowered their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Finally, StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock opened at $280.20 on Tuesday. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The stock has a 50 day moving average price of $331.62 and a 200-day moving average price of $334.10. Bio-Rad Laboratories, Inc. has a one year low of $262.12 and a one year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.